stocktitan.net

Polaryx Advances Q4 Start for SOTERIA Phase 2 Basket Trial

Polaryx Therapeutics logoPolaryx Therapeutics
Sig2.65Sen+6.75Env0.00Soc+3.35Gov+2.25

Polaryx Therapeutics advances readiness for its SOTERIA Phase 2 open-label basket trial of PLX-200 in pediatric CLN2, CLN3, Krabbe and Sandhoff diseases. The study is registered on ClinicalTrials.gov (NCT07740512) with FDA authorization, FDA Fast Track designation for PLX-200, an experienced CRO to support execution, and a completed $10 million financing to support initiation and key clinical milestones.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro